Engagement in Key Investor Conferences
Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company focused on innovative treatments for rare diseases, is preparing to participate in several significant investor conferences this November. These events represent a crucial opportunity for management to highlight their progress and upcoming projects, engaging with investors who are interested in the future of therapeutic development.
Details of Attended Events
Among the key events, Soleno will begin with the Guggenheim Healthcare Innovation Conference. Scheduled for November 11, this event will feature insights starting at 10:00 AM ET, offering a platform for management to share their vision and front-line initiatives.
The following week, Soleno will also attend the Stifel 2024 Healthcare Conference on November 18, where they are set to present at 4:45 PM ET. This conference is known for delving into the latest healthcare innovations, providing an excellent backdrop for discussions about Soleno’s groundbreaking therapeutic developments.
Following these, the prestigious Jefferies London Healthcare Conference will conclude their conference series on November 20 at 8:00 AM GT. This will be a valuable chance for outreach to a global investor audience.
Investment Opportunities and Insights
For those interested in the updates from the Guggenheim and Jefferies conferences, a live audio webcast will be available. Investors can access the webcasts and recordings via the Investors section on the Company’s website. By actively participating in these conferences, Soleno is not only aiming to attract investment but also foster a deeper understanding of their commitment to advancing healthcare solutions.
About Soleno's Therapeutic Focus
Soleno’s core mission is the development and commercialization of innovative therapies for rare diseases, underscoring a commitment to addressing unmet medical needs. The company has recently submitted a New Drug Application (NDA) to the FDA for its leading candidate, DCCR (diazoxide choline) extended-release tablets. This once-daily oral treatment has been developed specifically for Prader-Willi syndrome (PWS), a complex genetic disorder.
The company’s dedication to research and development is reflected in its Phase 3 development program, which has laid the groundwork for this submission. Soleno is poised to revolutionize the treatment landscape for patients suffering from rare diseases.
Looking Ahead
As Soleno Therapeutics prepares for these upcoming investor conferences, it continues to emphasize its innovative approach to tackling rare conditions. Their proactive engagement in these discussions signifies a broader aspiration to elevate the awareness of their therapies among potential investors and healthcare professionals alike.
With a focus on forging strong relationships with investors, Soleno seeks to secure additional funding opportunities, enabling them to accelerate their therapeutic programs and ultimately enhance patient outcomes.
Staying Connected
For updates and live coverage of the events, prospective investors are encouraged to check back frequently on Soleno’s official website, which is a resource for comprehensive information regarding their initiatives and future engagements.
Frequently Asked Questions
What events is Soleno Therapeutics participating in this November?
Soleno will attend the Guggenheim Healthcare Innovation Conference, Stifel 2024 Healthcare Conference, and Jefferies London Healthcare Conference.
What is the primary goal of these conferences for Soleno?
The primary goal is to engage with investors and share insights about their innovative treatments and progress in clinical trials.
What is DCCR?
DCCR (diazoxide choline) is an extended-release oral tablet developed by Soleno Therapeutics for the treatment of Prader-Willi syndrome.
Where can I find more information about these conferences?
Information including webcasts will be available in the Investors section of Soleno's official website.
Who can I contact for more information about Soleno?
For inquiries, you can contact Brian Ritchie at LifeSci Advisors, LLC via phone at 212-915-2578.
